Evidence map›Paper›PMID 34616270›Full record

ArticleCase reports in gastroenterology

Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment.

Aiko Murayama, Kazuto Tajiri, Atsuko Nakaya, Hiroyuki Ito, Yuka Hayashi, Toshiki Entani, Kohei Nagata, Shinichi Tanaka, Takeru Hamashima, Ichiro Yasuda

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Aiko MurayamaThe Third Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.
Kazuto TajiriThe Third Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.
Atsuko NakayaDepartment of Gastroenterology, Takaoka Municipal Hospital, Takaoka, Japan.
Hiroyuki ItoDepartment of Gastroenterology, Takaoka Municipal Hospital, Takaoka, Japan.
Yuka HayashiThe Third Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.
Toshiki EntaniThe Third Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.
Kohei NagataThe Third Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.
Shinichi TanakaThe First Department of Pathology, Faculty of Medicine, University of Toyama, Toyama, Japan.
Takeru HamashimaThe Second Department of Pathology, Faculty of Medicine, University of Toyama, Toyama, Japan.
Ichiro YasudaThe Third Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.
University of Toyama · JPKouseiren Takaoka Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increased use of immune-checkpoint inhibitors to treat various types of cancer has increased the incidence of immune-related adverse events (irAEs). Hepatic irAEs are frequent and can lead to serious conditions. Among the various types of hepatic irAEs reported to date, bile duct injury has been shown refractory to steroid treatment. This study describes 2 patients with hepatic irAEs manifesting as intrahepatic bile duct injury. Immunostaining with antibodies to both CD8 and cytokeratin-7 was useful for the diagnosis, and both patients were refractory to steroid treatment. Prompt diagnosis and active immunosuppressive therapies are required in such cases.

Indexed as

CholangitisCytokeratin-7Immune-checkpoint inhibitorsImmune-related adverse eventsMycophenolate mofetil

Identifiers

PMID34616270
PMCPMC8454244
OpenAlexW3197645871

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.